Reiki Therapy to Improve Key Symptoms in Integrative Oncology Clinic (REIKI)

Description

The purpose of this research is to investigate the delivery of Reiki to integrative oncology patients and assess its potential for improving cancer-related symptoms in this population.

Conditions

Cancer Pain, Oncology Pain

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this research is to investigate the delivery of Reiki to integrative oncology patients and assess its potential for improving cancer-related symptoms in this population.

Reiki Therapy to Improve Key Symptoms in Integrative Oncology Clinic (REIKI)

Reiki Therapy to Improve Key Symptoms in Integrative Oncology Clinic (REIKI)

Condition
Cancer Pain
Intervention / Treatment

-

Contacts and Locations

Cleveland

University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States, 44106

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18 - 89.
  • * Neoplasm diagnosis (i.e., ICD-10 C00 - D49) confirmed in electronic health record (EHR)/Caisis
  • * Receiving care at a UH Connor Whole Health Integrative Oncology Clinic.
  • * Reporting at least three ESAS symptoms ≥4/10 at baseline screening including fatigue and ≥2 other symptoms on the 9-item questionnaire.
  • * Able to speak and understand English.
  • * Has an email address, and access to a computer with internet and/or a mobile device with a functioning data plan
  • * Significant cognitive impairment that has not been corrected.
  • * Significant visual impairment that has not been corrected.
  • * Unable to provide informed consent.
  • * Active psychosis.
  • * Pregnancy.
  • * Metastatic disease.
  • * Reiki therapy within 3 months of study enrollment
  • * Active immunotherapy, chemotherapy, or radiation treatment, or completed within 3 months before study start. Aromatase inhibitors and tamoxifen are exceptions.

Ages Eligible for Study

18 Years to 89 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Case Comprehensive Cancer Center,

Santosh Rao, MD, PRINCIPAL_INVESTIGATOR, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center

Study Record Dates

2025-03-31